Head-to-head · free
iRhythm Technologies, Inc. vs LB Pharmaceuticals
IRTC vs LBRX — return on capital, cash generation, margins and balance sheet side by side.
IRTC
2 / 3
measures where IRTC leads
LBRX
1 / 3
measures where LBRX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | IRTC · FY2025 | LBRX · FY2025 |
|---|---|---|
| Revenue | $747.1M | — |
| Net income | (44.6M) | (25.2M) |
| Revenue growth (yearly, multi-year) | 23.3% | — |
| Free cash flow | $34.5M | (35.3M) |
| Free cash flow margin | 4.6% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -36.6% | — |
| Gross margin | 70.6% | — |
| Operating margin | -6.7% | — |
| Net debt / EBITDA | -13.37x | 8.32x |
Figures are as reported by each company; latest fiscal year shown.
Where iRhythm Technologies, Inc.'s cash went (FY2025)
- Capital spending
- $46.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where LB Pharmaceuticals's cash went (FY2025)
- Capital spending
- $52000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free